AIM: The objective of this study is to assess the contribution of ADIPOQ variants to type 2 diabetes in Japanese Brazilians. METHODS: We genotyped 200 patients with diabetes mellitus (100 male and 100 female, aged 55.0 years [47.5-64.0 years]) and 200 control subjects with normal glucose tolerant (NGT) (72 male and 128 female, aged 52.0 years [43.5-64.5 years]). RESULTS: Whereas each polymorphism studied (T45G, G276T, and A349G) was not significantly associated with type 2 diabetes mellitus, the haplotype GGA was overrepresented in our diabetic population (9.3% against 3.1% in NGT individuals, P=.0003). Also, this haplotype was associated with decreased levels of adiponectin. We also identified three mutations in exon 3: I164T, R221S, and H241P, but, owing to the low frequencies of them, associations with type 2 diabetes could not be evaluated. The subjects carrying the R221S mutation had plasma adiponectin levels lower than those without the mutation (2.10 microg/ml [1.35-2.55 microg/ml] vs. 6.68 microg/ml [3.90-11.23 microg/ml], P=.015). Similarly, the I164T mutation carriers had mean plasma adiponectin levels lower than those noncarriers (3.73 microg/ml [3.10-4.35 microg/ml] vs. 6.68 microg/ml [3.90-11.23 microg/ml]), but this difference was not significant (P=.17). CONCLUSIONS: We identified in the ADIPOQ gene a risk haplotype for type 2 diabetes in the Japanese Brazilian population.
AIM: The objective of this study is to assess the contribution of ADIPOQ variants to type 2 diabetes in Japanese Brazilians. METHODS: We genotyped 200 patients with diabetes mellitus (100 male and 100 female, aged 55.0 years [47.5-64.0 years]) and 200 control subjects with normal glucose tolerant (NGT) (72 male and 128 female, aged 52.0 years [43.5-64.5 years]). RESULTS: Whereas each polymorphism studied (T45G, G276T, and A349G) was not significantly associated with type 2 diabetes mellitus, the haplotype GGA was overrepresented in our diabetic population (9.3% against 3.1% in NGT individuals, P=.0003). Also, this haplotype was associated with decreased levels of adiponectin. We also identified three mutations in exon 3: I164T, R221S, and H241P, but, owing to the low frequencies of them, associations with type 2 diabetes could not be evaluated. The subjects carrying the R221S mutation had plasma adiponectin levels lower than those without the mutation (2.10 microg/ml [1.35-2.55 microg/ml] vs. 6.68 microg/ml [3.90-11.23 microg/ml], P=.015). Similarly, the I164T mutation carriers had mean plasma adiponectin levels lower than those noncarriers (3.73 microg/ml [3.10-4.35 microg/ml] vs. 6.68 microg/ml [3.90-11.23 microg/ml]), but this difference was not significant (P=.17). CONCLUSIONS: We identified in the ADIPOQ gene a risk haplotype for type 2 diabetes in the Japanese Brazilian population.
Authors: L Y Han; Q H Wu; M L Jiao; Y H Hao; L B Liang; L J Gao; D G Legge; H Quan; M M Zhao; N Ning; Z Kang; H Sun Journal: Diabetologia Date: 2011-06-03 Impact factor: 10.122
Authors: Damien C Croteau-Chonka; Ying Wu; Yun Li; Marie P Fogarty; Leslie A Lange; Christopher W Kuzawa; Thomas W McDade; Judith B Borja; Jingchun Luo; Omar AbdelBaky; Terry P Combs; Linda S Adair; Ethan M Lange; Karen L Mohlke Journal: Hum Mol Genet Date: 2011-10-18 Impact factor: 6.150
Authors: Hanieh Yaghootkar; Claudia Lamina; Robert A Scott; Zari Dastani; Marie-France Hivert; Liling L Warren; Alena Stancáková; Sarah G Buxbaum; Leo-Pekka Lyytikäinen; Peter Henneman; Ying Wu; Chloe Y Y Cheung; James S Pankow; Anne U Jackson; Stefan Gustafsson; Jing Hua Zhao; Christie M Ballantyne; Weijia Xie; Richard N Bergman; Michael Boehnke; Fatiha el Bouazzaoui; Francis S Collins; Sandra H Dunn; Josee Dupuis; Nita G Forouhi; Christopher Gillson; Andrew T Hattersley; Jaeyoung Hong; Mika Kähönen; Johanna Kuusisto; Lyudmyla Kedenko; Florian Kronenberg; Alessandro Doria; Themistocles L Assimes; Ele Ferrannini; Torben Hansen; Ke Hao; Hans Häring; Joshua W Knowles; Cecilia M Lindgren; John J Nolan; Jussi Paananen; Oluf Pedersen; Thomas Quertermous; Ulf Smith; Terho Lehtimäki; Ching-Ti Liu; Ruth J F Loos; Mark I McCarthy; Andrew D Morris; Ramachandran S Vasan; Tim D Spector; Tanya M Teslovich; Jaakko Tuomilehto; Ko Willems van Dijk; Jorma S Viikari; Na Zhu; Claudia Langenberg; Erik Ingelsson; Robert K Semple; Alan R Sinaiko; Colin N A Palmer; Mark Walker; Karen S L Lam; Bernhard Paulweber; Karen L Mohlke; Cornelia van Duijn; Olli T Raitakari; Aurelian Bidulescu; Nick J Wareham; Markku Laakso; Dawn M Waterworth; Debbie A Lawlor; James B Meigs; J Brent Richards; Timothy M Frayling Journal: Diabetes Date: 2013-07-08 Impact factor: 9.461